Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22009525 | 0.88 | MEN1 (0.45) | MEN1KMT2ARIPK1HPGDHTT | |
| SCHEMBL13186808 | 0.78 | KMT2A (0.47) | MEN1KMT2AHPGDL3MBTL1NPC1 | |
| SCHEMBL29036558 | 0.77 | KMT2A (0.50) | MEN1KMT2AHPGDNPC1RAB9A | |
| SCHEMBL888875 | 0.76 | ALDH1A1 (0.51) | MEN1KMT2AHPGDNPC1RAB9A | |
| SCHEMBL13138717 | 0.74 | MEN1 (0.51) | MEN1KMT2AHPGDNPC1RAB9A | |
| SCHEMBL19889937 | 0.71 | MEN1 (0.44) | MEN1KMT2ARIPK1HPGDL3MBTL1 | |
| SCHEMBL13151737 | 0.70 | MEN1 (0.50) | MEN1KMT2ARIPK1HTTL3MBTL1 | |
| SCHEMBL20475967 | 0.69 | LMNA (0.47) | MEN1KMT2ARIPK1HTTL3MBTL1 | |
| SCHEMBL1697396 | 0.69 | LMNA (0.47) | MEN1KMT2ARIPK1HTTL3MBTL1 | |
| SCHEMBL11767495 | 0.68 | MEN1 (0.51) | MEN1KMT2ARIPK1HTTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001609-B2 | Cell permeable cyclic peptide scaffolds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-11 | — | — | US | disclosed |
| US-20200157149-A1 | Cell Permeable Cyclic Peptide Scaffolds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11001609-B2 | Cell permeable cyclic peptide scaffolds | VIP, IAPP, HM13 | MEN1 1421/4885KMT2A 4867/4885RIPK1 2351/4885 |
| US-20200157149-A1 | Cell Permeable Cyclic Peptide Scaffolds | VIP, IAPP, HM13 | MEN1 1421/4885KMT2A 4867/4885RIPK1 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.